Crucell Announces PER.C6 and AdVac Technology License Agreement with Wyeth Pharmaceuticals
31 Jul 2007 -
Crucell N.V. announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth. Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed. Crucell's AdVac® technology is a recombinant
vector technology used to develop novel adenoviral-based products. PER.C6® technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.
Top
Contact
Print version
PDF version
Send article
RSS-Feed
